All In Biotech

Drug Trial Radar · NCT07777822

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Aug 14, 2026

Primary completion

Oct 2029

Study completion Feb 2031

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Conditions

  • NSCLC
  • Non-small Cell Lung Cancer
  • Non-Small Cell Lung Cancer NSCLC
  • Non-Squamous Non Small Cell Lung Cancer
  • Lung Cancer (NSCLC)
  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Metastatic Non-Squamous Non-Small Cell Lung Cancer

Interventions

  • zoldonrasibDrug

    oral tablets

  • PlaceboDrug

    oral tablets

  • pembrolizumabDrug

    IV infusion or Subcutaneous injection

  • pemetrexed + cisplatin /carboplatinDrug

    IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Up to approximately 5 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • Helios CR, Inc. - The Oncology Institute of Hope and Innovation - Fort Lauderdale

    Fort Lauderdale, Florida · Recruiting

  • Florida Clinical Trials Group, LLC

    Plantation, Florida · Recruiting

  • Florida Clinical Trials Group

    Plantation, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.